The role of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation has also been suggested in the development of resistance to anti-leukemic drugs and various NF-κB inhibitors have shown to successfully eradicate cancer stems cells; however, the inhibition of NF-κB alone is not sufficient to eradicate the AML stem cells [25]. This evidence concerns the gene NFKB1 and acute myeloid leukemia.